Why the study?
Does betaxolol affect quality of life in newly diagnosed hypertensive subjects compared to placebo?
Does betaxolol affect quality of life in newly diagnosed hypertensive subjects compared to placebo?
Labeling and treating newly diagnosed hypertension with betaxolol does not significantly impair quality of life, likely because the positive effects of increased medical attention outweigh potential negative effects.
Betaxolol preserves quality of life in newly diagnosed hypertensives; confirms negligible labeling effects while extending data on beta-blocker cognitive impact.
In an experimental study, 150 general practitioners studied 468 apparently healthy subjects whose blood pressure (BP) level was unknown or had not been measured for 1 year. The study lasted for 10 weeks. If BP was greater than 95 mm Hg on the first two visits, subjects were randomized into two experimental groups for 8 weeks, with cross-over from betaxolol to placebo and vice versa after 4 weeks. Quality of life was measured at visits 1, 3 (2 weeks), 5 (6 weeks), and 7 (10 weeks) in five ways: well-being, physical state, sexual functioning, sleep, and cognitive acuity. BP level appeared to be effectively controlled by betaxolol as compared with placebo. The results show that no effects on quality of life could be detected by labeling subjects as hypertensives. Equally, almost no effects of active treatment could be established. Learning effects on the two cognitive acuity measurements used were attenuated by betaxolol, however. Apparently, in a carefully controlled study, the effects of increased medical attention and care outweight the potentially negative effects of labeling and treatment.
No takes yet. Share an insight, caveat, or question.
Ameling et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: